Research funded by Project Cure CRC
Innovation is in progress.
Innovation is in progress.
The Alliance’s Project Cure CRC continues to make global investments based on expert recommendations and areas of urgent necessity, outlined in this request for proposals. Awardees are listed below.
Dr. Kalluri of MD Anderson Cancer Center aims to develop urgently needed therapeutic options for the 96% of colorectal cancer patients with microsatellite stable (MSS) disease.
H. Charles Manning, PhD, a professor at MD Anderson Cancer Center, will lead a collaborative effort to discover the first theranostic pair for imaging and therapy for patients with CRC.
Dr. Peter Lee of City of Hope will pursue a novel combination immunotherapy to treat metastatic MSS colorectal cancer, which does not respond well to current treatments.
Kevin Van Der Jeught, PhD, of the University of Miami, seeks to improve intratumoral mRNA vaccination strategies by targeting immune checkpoints to enhance anti-tumor immune responses.
Ekaterina Dadachova, PhD, of The University of Saskatchewan will investigate combining targeted radiation with immunotherapies for a novel and synergistic approach to treat advanced colorectal cancer, improving clinical outcomes.
Yekaterina Y. Zaytseva, PhD, of the University of Kentucky, will investigate new drug combinations to kill CRC cells with a BRAF mutation. These cells currently have a low response rate to existing treatments.
Dr. Masood of Indiana University is studying ProAgio, a new protein that targets cells aiding cancer's survival. This approach could improve therapies for tough-to-treat tumors.
Dr. Suelzu of Anglia Ruskin University will investigate how fat tissue impacts the growth and spread of colorectal cancer, especially in people with obesity.
Dr. Carnevale of UCSF will use cutting-edge technology to target multiple genes at once, seeking to uncover weaknesses in cancer cells and boost the body’s immune response.
Dr. Robbins of Georgetown University aims to target and stop the circulating tumor cells responsible for forming metastatic tumors. Success could improve mCRC survival rates.
million in funding allocated
projects supported
million funding goal
Project Cure CRC seeks research proposals from early-career investigators, senior investigators, teams, startup companies, and others. We prioritize collaboration toward curative science.
The Alliance's Project Cure CRC announces $1.3 million in new research grants — bringing total funding to nearly $12 million — to drive breakthroughs in colorectal cancer care and address critical research gaps.
The 2025 ASCO Annual Meeting featured several important studies that could change how colorectal cancer is treated, including a pivotal study for BRAF V600E patients.